IAP antagonization promotes inflammatory destruction of vascular endothelium

• Published in: EMBO reports 2015-06, Vol.16 (6), p.719-727
• Main Authors: Witt, Axel, Seeger, Jens M, Coutelle, Oliver, Zigrino, Paola, Broxtermann, Pia, Andree, Maria, Brinkmann, Kerstin, Jüngst, Christian, Schauss, Astrid C, Schüll, Stephan, Wohlleber, Dirk, Knolle, Percy A, Krönke, Martin, Mauch, Cornelia, Kashkar, Hamid
• Format: Article
• Language: English
• Subjects: angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Apoptosis; Apoptosis - drug effects; Blood vessels; Cytotoxicity; EMBO03; EMBO05; EMBO07; Endothelium; Endothelium, Vascular - pathology; IAPs; Inflammation - physiopathology; Inhibitor of Apoptosis Proteins - antagonists & inhibitors; Melanoma; Melanoma, Experimental - blood supply; Melanoma, Experimental - drug therapy; Melanoma, Experimental - metabolism; Melanoma, Experimental - pathology; Mice; Mice, Knockout; Mortality; Neovascularization, Pathologic; NF-kappa B - metabolism; Proteins; Receptors, Tumor Necrosis Factor - genetics; Rodents; Scientific Report; Scientific Reports; TNF; tumor; Tumor Necrosis Factor-alpha - metabolism; Tumors
• ISSN: 1469-221X; 1469-3178
• DOI: 10.15252/embr.201439616

In this study, we show for the first time that the therapeutic antagonization of inhibitor of apoptosis proteins (IAPs) inhibits B16 melanoma growth by disrupting tumor vasculature. Specifically, the treatment of mice bearing B16 melanoma with an IAP antagonist compound A (Comp A) inhibits tumor growth not by inducing direct cytotoxicity against B16 cells but rather by a hitherto unrecognized antiangiogenic activity against tumor vessels. Our detailed analysis showed that Comp A treatment induces NF‐κB activity in B16 tumor cells and facilitates the production of TNF. In the presence of Comp A, endothelial cells (ECs) become highly susceptible to TNF and undergo apoptotic cell death. Accordingly, the antiangiogenic and growth‐attenuating effects of Comp A treatment were completely abolished in TNF‐R knockout mice. This novel targeting approach could be of clinical value in controlling pathological neoangiogenesis under inflammatory condition while sparing blood vessels under normal condition. Synopsis Treatment of mice bearing B16 melanomas with an IAP antagonist (Comp A) inhibits tumor growth by disrupting the tumor vasculature. Upon exposure to Comp A tumor cells produce TNF, which together with Comp A induces endothelial cell death. Inhibition of IAPs induces NF‐κB activity in tumor cells and leads to TNF production. The increased local concentration of TNF in the tumor microenvironment together with Comp A induces endothelial cell death. IAP inhibition promotes inflammatory destruction of tumor‐associated vascular endothelium and attenuates tumor growth while minimizing collateral damage to normal blood vessels. Graphical Abstract Treatment of mice bearing B16 melanomas with an IAP antagonist (Comp A) inhibits tumor growth by disrupting the tumor vasculature. Upon exposure to Comp A tumor cells produce TNF, which together with Comp A induces endothelial cell death.